You are here:Home-Community manager
Community manager

About Community manager

This author has not yet filled in any details.
So far Community manager has created 137 blog entries.

Manipulating the host response to treat infections

Speakers: R.E.W. (Bob) Hancock, University of British Columbia (Canada) Henk P. Haagsman, Utrecht University (Netherlands) Moderator: Neeloffer Mookherjee, Departments of Internal Medicine and Immunology, University of Manitoba (Canada) Presentations: Immune modulation and host directed therapies as an adjunctive approach to treating infections (R.E.W. (Bob) Hancock): Host defence peptides (HDP; often termed antimicrobial peptides) stimulate protective immunity while suppressing potentially harmful inflammation. Both of these activities can assist in anti-infective therapy. HDPs work as immune modulators in animal models against

Manipulating the host response to treat infections2020-11-25T09:50:51+00:00


Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic
– by Markus Heep, Esther Bettiol, Tanyaporn Wansom and Hilary Johnstone

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Zoliflodacin is an oral antibiotic with a novel mode of action distinct from quinolones. The majority of uncomplicated urogenital and rectal gonococcal infections were successfully treated with oral zoliflodacin in


Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic
– by Markus Heep, Esther Bettiol, Tanyaporn Wansom and Hilary Johnstone
2020-10-15T11:38:21+00:00

Top 10 mistakes in antibacterial development

Expert campus: 'Top 10 mistakes in antibacterial development' 4th AMR Conference, 24-28 August 2020, virtual event Moderator: Ursula Theuretzbacher, Founder, CEFAIA Speakers: Peter Warn, formerly SVP, Anti-infective Discovery, Evotec Richard Knight, Director & Co–founder, ApconiX Aleksander Danilovski, CSO & Senior Vice President Global R&D and Regulatory Affairs, Xelia Jointly organized by:                      

Top 10 mistakes in antibacterial development2020-10-15T08:43:19+00:00

Saving childrens’ lives – treating neonatal sepsis

Speakers: Prof Hanan Balkhy, Assistant Director-General for Antimicrobial resistance, WHO Dr Manica Balasegaram, Executive Director, GARDP Dr Dhanya Dharmapalan, paediatrician and member of the Pediatric Infectious Disease Society (PIDS), Mumbai Dr Borna Nyaoke, Senior Clinical Project Manager, DNDi/GARDP Kenya Moderator: Dr Peter Beyer, Senior Advisor, AMR Division, WHO The webinar, organized in collaboration with WHO, was held on the occasion of Universal Children’s Day and during World Antimicrobial Awareness Week 2020. It focused on the challenges in treating newborns

Saving childrens’ lives – treating neonatal sepsis2020-11-24T14:48:04+00:00


Why we need a new access model for antibiotics
– by Yann Ferrisse and Fernando Pascual Martinez

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The challenge of access to antibiotics Whether it concerns an old or new antibiotic, access to these drugs represents a major challenge globally and this is not a recent problem.


Why we need a new access model for antibiotics
– by Yann Ferrisse and Fernando Pascual Martinez
2020-10-01T14:47:24+00:00

Developing antibiotics for children – medical need and regulatory challenges

Download the speakers' slides here! Speakers: Phoebe Williams, Sydney Children's Hospital and University of Sydney (Australia) Irja Lutsar, University of Tartu (Estonia) Moderator: Sally Ellis (GARDP) Phoebe's presentation discussed: Status quo – what antibiotics do we have (left) for children and babies Where is the biggest medical need? Challenges of clinical trials in children – the clinicians perspective What impact will new drugs have in day-to-day practice and how does this depend on the setting (e.g. LMICs vs.

Developing antibiotics for children – medical need and regulatory challenges2020-11-04T08:46:01+00:00

Exploring safety issues in antimicrobial drug development

Presentations & speakers: Drug-induced neurotoxicity Will Redfern, Certara Mitochondria and antimicrobial induced toxicity: In vitro assays to aid drug development Julie Eakins, Cyprotex Quantitative systems toxicology and antibiotic development Paul B. Watkins, UNC Institute for Drug Safety Sciences Moderator: Claire Sadler, Apconix This webinar was developed in collaboration with CARB-X, JPIAMR, REPAIR Impact Fund, Wellcome Trust, ASM and ESCMID. It is part of the 'Antibiotic Bootcamps for Developers' series which have been developed by GARDP and its partners at the 'ASM/ESCMID

Exploring safety issues in antimicrobial drug development2020-10-13T15:06:10+00:00

Moving from preclinical to clinical-stage: Challenges & opportunities

Presentations & speakers: Value of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience Bala Subramanian, Bugworks Research Inc. Amicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections Michael P. Bevilacqua, Amicrobe, Inc. Discovery and development of microbiome therapeutics using reverse translation Matthew Henn & Chris Ford, Seres Therapeutics Development of a multi-component toxoid vaccine for S. aureus - Regulatory challenges and opportunities M. Javad Aman & Catherine Bernard,

Moving from preclinical to clinical-stage: Challenges & opportunities2020-10-09T08:34:02+00:00

The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study

Speakers: Anand Anandkumar, Co-founder and CEO Bugworks Research Inc (India) Kamini Walia, Program Officer, ICMR-AMR Initiative (India)  Moderator: François Franceschi, GARDP  In this webinar, Anand Anandkumar and Kamini Walia discussed: Why is India one of the hotbeds of the AMR problem? Latest statistics of growing drug resistance etc. Initiatives of the Indian Government to curb the AMR problem Antimicrobial R&D landscape in India – a vibrant ecosystem supporting innovation in AMR diagnosis, prevention and therapeutics Fledgling antimicrobial clinical trial

The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study2020-11-03T10:42:32+00:00

Clinical development of antimicrobials – Phase 1 development challenges

Speaker: Markus Zeitlinger, Head of Department, Department of Clinical Pharmacology, Medical University of Vienna (Austria) Moderator: Markus Heep, Medical Lead Zoliflodacin programme, GARDP (Switzerland) In this webinar, Markus Zeitlinger gave an overview of different goals of phase 1 studies of antibiotic drug development. Topics discussed included: Combination of several aims in one study What do I need to extrapolate antimicrobial efficacy based on phase 1 Most frequent questions during scientific advice This live webinar including interactive Q&A session was

Clinical development of antimicrobials – Phase 1 development challenges2020-10-09T08:35:04+00:00

Putting children first in the fight against antibiotic resistance

Globally, sepsis is a leading cause of death in children under 5. This unacceptable and preventable health crisis is worsened by drug resistance. Up to 40% of bacterial infections in newborns are resistant to standard treatments and more than 214,000 babies die each year from resistant infections. It is time to put children first in the fight against antibiotic resistance. This webinar explored the threat of antibiotic resistance for children under 5, the unique challenges of antibiotic research and

Putting children first in the fight against antibiotic resistance2020-06-29T14:51:16+00:00


COVID-19 und warum die stille Krise der arzneimittelresistenten Infektionen wichtiger ist denn je
– von Manica Balasegaram

Das Schreckgespenst einer Infektionskrankheit, die sich als Pandemie ausbreitet und an der Zehntausende von Menschen auf der ganzen Welt sterben, ist kein theoretisches Alptraumszenario mehr. Die „Krankheit X“ der Weltgesundheitsorganisation (WHO) ist da, und trotz konsequenter Bemühungen der WHO und anderer Akteure, diese Bedrohung im politischen Fokus zu halten, ist die Welt weitgehend unvorbereitet getroffen worden. Wenn es bereits Lehren aus der Pandemie der durch das Coronavirus SARS-CoV-2 verursachten Erkrankung (COVID-19) zu ziehen gibt, dann die, dass zu viele


COVID-19 und warum die stille Krise der arzneimittelresistenten Infektionen wichtiger ist denn je
– von Manica Balasegaram
2020-04-16T07:51:42+00:00

Assay development for measuring antibiotic accumulation in Gram-negative bacteria

Speakers: Jessica Blair, Institute of Microbiology and Infection, University of Birmingham, UK Mark Brönstrup, Department of Chemical Biology, Helmholtz Centre for Infection Research, Germany David A. Six, Venatorx Pharmaceuticals, Inc., US Moderator: Alice Erwin, Erwin Consulting LLC, US * This webinar was developed in collaboration with The Pew Charitable Trusts. * This live webinar including interactive Q&A session was broadcast on 19 May 2020. If you have questions or comments, please let us know. Do so by submitting them

Assay development for measuring antibiotic accumulation in Gram-negative bacteria2020-07-31T08:33:52+00:00


The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation
– by Ryan Cirz and Kevin Krause

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” There is a growing awareness that companies with newly approved antibiotics face substantial economic challenges. Yet we remain concerned that there is a general lack of understanding of the mechanics


The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation
– by Ryan Cirz and Kevin Krause
2020-05-07T14:08:12+00:00

Inhaled antimicrobials: Do we get the drug to the bug?

Speaker: Harm A. W. M. Tiddens, Professor of Pediatric Pulmonology and Allergology, Erasmus Medical Center Sophia Children’s Hospital (Netherlands) Moderator: Harpal Singh Dhillon, Global Medical Value Director & Founder, AntiBx (UK) In this webinar, Harm Tiddens discussed the relation between structural and functional abnormalities of the lung and how this can impact upon the deposition pattern and efficacy of inhaled antibiotics. He also presented the learnings of his research group’s computational fluid dynamic modelling studies and explained why the

Inhaled antimicrobials: Do we get the drug to the bug?2020-06-22T13:18:13+00:00


Diagnostics to safeguard new and current antibiotics for gonorrhoea
– by Cassandra Kelly-Cirino and Cecilia Ferreyra

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Gonorrhoea and chlamydia are the two most common sexually transmitted infections (STIs) in the world, with a staggering 214 million new cases occurring in 2016 alone.1 While anyone having unprotected


Diagnostics to safeguard new and current antibiotics for gonorrhoea
– by Cassandra Kelly-Cirino and Cecilia Ferreyra
2020-05-07T14:05:13+00:00

Non-traditional antibacterial therapeutic options and challenges

Speaker: Ursula Theuretzbacher, CEFAIA (Austria) Moderator: Prabhavathi Fernandes, Chair of GARDP's Scientific Advisory Committee (USA) In this webinar, Ursula Theuretzbacher discussed the following aspects of non-traditional antibacterial therapeutics: Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation. Some of these approaches require novel preclinical efficacy models to predict clinical outcome Pathogen-specific or even patient-specific

Non-traditional antibacterial therapeutic options and challenges2020-02-05T13:33:15+00:00

Testing for the potential of emergence of antimicrobial resistance

Speaker: Michael Mourez, Head BacteriOmics Platform, Evotec, France Moderator: Laura Piddock, Director Scientific Affairs, GARDP In this webinar, the following aspects were presented: What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques? What are some techniques that may be used to understand the origins of resistance selection? How to rationalize/manage the risk of translation of

Testing for the potential of emergence of antimicrobial resistance2020-01-22T15:33:25+00:00


On fireworks and finding ways to address drug-resistance in low- and middle-income countries
– by Ramanan Laxminarayan

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Every autumn the Diwali festival is celebrated with food, gifts and fireworks. Ramanan Laxminarayan, Chair of the Board of the Global Antibiotic Research and Development Partnership (GARDP) reflects on India’s


On fireworks and finding ways to address drug-resistance in low- and middle-income countries
– by Ramanan Laxminarayan
2020-05-07T14:05:31+00:00

Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)

Antibiotic Bootcamps for Developers: Post-Approval Economics for New Antibiotics ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 3-6 September 2019, Boston Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust Moderator: Ryan Cirz Speakers: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and formerly Achaogen), Rolf Wagenaar (CD&E Consulting LLC, U.S.) Q&A session: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and

Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)2019-11-29T13:11:04+00:00

Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process (ASM/ESCMID 2019)

Antibiotic Bootcamps for Developers: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 3-6 September 2019, Boston Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund, JPIAMR and Wellcome Trust Moderator: Ursula Theuretzbacher (Center for Anti-Infective Agents, Austria) Speakers: Michael Mourez (Evotec, France), Douglas Huseby (University Uppsala, Sweden) Q&A session: Michael Mourez (Evotec, France), Douglas Huseby (University Uppsala, Sweden), Mariana Castanheira (JMI Laboratories, U.S.), Ursula Theuretzbacher (Center

Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process (ASM/ESCMID 2019)2020-01-20T08:43:32+00:00


Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why
– by Tim Jinks

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial resistance has a language problem, and we’ve known it for a while. Back in 2015, Wellcome published research revealing that people in the UK have little awareness of the


Talking about the ‘antibiotic apocalypse’ won’t encourage public action – here’s why
– by Tim Jinks
2020-05-07T16:33:58+00:00


A new cephalosporin has been approved
– by Ursula Theuretzbacher

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” After approval of four new ß-lactamase inhibitor (BLI) combinations in the last five years, a new member of the ß-lactam class made it to the finish line. On November 14,


A new cephalosporin has been approved
– by Ursula Theuretzbacher
2020-05-07T16:34:04+00:00

Innovation in point-of-care diagnostics for sepsis and bloodstream infections

Download the speakers' slides here! Speakers: Till Bachmann, University of Edinburgh, UK Amrita Sukrity, SpotSense, India David Anderson, Burnet Institute, Australia Moderator: Caroline Purslow, Nesta Challenges In this webinar our moderator Caroline Purslow (Nesta Challenges) welcomed three speakers. Till Bachmann gave an overview of recent advances in AMR diagnostics development. He discussed: State of the art approaches for diagnosing infections and AMR Pipeline of promising tests Challenges of adoption Amrita Sukrity drew from her experience as a founder

Innovation in point-of-care diagnostics for sepsis and bloodstream infections2019-12-04T14:41:28+00:00


Lessons from a recent outbreak of carbapenem-resistant Klebsiella pneumoniae in a neonatal unit
– by Adrie Bekker

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Our hospital is a tertiary referral centre in South Africa that manages up to 8000 high-risk deliveries per year of which 45% of newborns are of low birth weight (<


Lessons from a recent outbreak of carbapenem-resistant Klebsiella pneumoniae in a neonatal unit
– by Adrie Bekker
2020-05-07T16:35:32+00:00

Structure Activity Relationships and Additivity — Going Beyond Conventional Wisdom

On 19 September, CDD will host a webinar about Structure Activity Relationships and Additivity. Drs. James “Guy” Breitenbucher and Peter Gedeck will talk about what’s new with theory, experiments, and technologies for better understanding SAR and additivity (and non-additivity). The discussion will focus on: Where SAR broke the traditional additivity rules What frameworks are most practical for understanding different types of underlying SAR patterns New technologies to more rapidly traverse SAR fragment lattices just invented To register for this

Structure Activity Relationships and Additivity — Going Beyond Conventional Wisdom2019-09-10T11:40:54+00:00

Converting Gram-positive-only compounds into broad-spectrum antibiotics

Speaker: Paul Hergenrother, Kenneth L. Rinehart Endowed Chair in Natural Products Chemistry, Department of Chemistry and the Institute for Genomic Biology, University of Illinois, US Moderator: Laura Piddock, Director of Scientific Affairs, GARDP In this webinar, Paul detailed his research group's efforts to understand compound accumulation in the Gram-negative ESKAPE pathogens. Emphasis was placed on the practicality, actionability, and translatability of this information, specifically, the use of accumulation rules to convert high-value Gram-positive-only compounds into antibiotics with activity against

Converting Gram-positive-only compounds into broad-spectrum antibiotics2019-11-08T15:36:09+00:00


Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel?
– by Colm Leonard & Tracy Parker

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The Global Action Plan on antimicrobial resistance (AMR), endorsed at the World Health Assembly in May 2015, recognised the need for sustainable and increased investment in new medicines, diagnostic tools,


Journey towards a better antimicrobial pipeline; is there light at the end of the tunnel?
– by Colm Leonard & Tracy Parker
2020-05-07T16:40:27+00:00

Natural product antibiotics: from traditional screening to novel discovery approaches

Speaker: Olga Genilloud, Scientific Director, Fundación MEDINA, Granada, Spain Moderator: Laura Piddock, Director of Scientific Affairs, GARDP In this webinar, Olga Genilloud discussed the role of natural products in current antibiotic discovery. Topics included: Screening strategies to identify novel antibiotics Current challenges and novel analytical tools New omic approaches supporting antibiotic discovery The presentation was followed by a Q&A session. This live webinar including interactive Q&A session was broadcast on 3 October 2019. If you have questions or comments,

Natural product antibiotics: from traditional screening to novel discovery approaches2019-10-04T12:21:16+00:00

Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research

Speaker: Peter Warn, Senior Vice President, Anti-infective Discovery, Evotec Moderator: William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy In this webinar, Peter Warn reviewed the experimental design and conduct of advanced or complex animal models for antimicrobial research. This webinar is designed as a follow on from the webinar of William J. Weiss: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research. Topics covered in this webinar

Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research2019-09-13T09:52:24+00:00


Addressing Gram-negative permeation & efflux evasion with a collaborative discovery tool
– by Wes Kim & Katie Prosen

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The antibiotics pipeline is insufficient to address the growing public health threat posed by Gram-negative ESKAPE pathogens—which are among the hardest to treat—and by other antibiotic-resistant bacteria. Of the 42


Addressing Gram-negative permeation & efflux evasion with a collaborative discovery tool
– by Wes Kim & Katie Prosen
2020-05-07T16:36:08+00:00

Enabling Academia to Fill the Discovery Gap

Meet-the-experts session (S386): 'Enabling Academia to Fill the Discovery Gap ' ASM Microbe, 24 June 2019, San Francisco Learnings from Industry and Funders Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Bridging the Gap: NIAID Resources to Facilitate Discovery and Development of Anti-Infectives Robin Broughton, NIAID/NIH, Rockville, MD Find all details here to join us at this session! Jointly organized with:                  

Enabling Academia to Fill the Discovery Gap2019-06-07T09:12:03+00:00

Better Science Through Metadata

On 13 June, CDD will host a webinar about the importance of metadata to increase reproducibility and productivity across the scientific community. Speakers: Ellen L. Berg, Chief Scientific Officer, Translational Biology for Eurofins Discovery Isabella Feierberg, Associate Principal Scientist, AstraZeneca To register for this webinar, please visit the CDD website.

Better Science Through Metadata2019-06-07T08:39:58+00:00

Models for antimicrobial R&D:
Computational modelling for population PK and PKPD

Speakers: Lena Friberg & Elisabet Nielsen, Department of Pharmaceutical Biosciences, Uppsala University, Sweden Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria In this webinar, Lena Friberg and Elisabet Nielsen discussed: Population PK modelling to characterize drug exposure and variability PKPD-modelling to characterize preclinical time-kill data PKPD-modelling for translation to patients Model-based dose-individualization This live webinar including interactive Q&A session was broadcast on 20 August 2019. If you have questions or comments, please let us know. Do so by

Models for antimicrobial R&D:
Computational modelling for population PK and PKPD
2019-08-23T07:49:49+00:00

CARB-X 2019 Funding Rounds Webinar

Thursday, May 16, 2019 03:00 PM CEST - 04:00 PM CEST Kevin Outterson, CARB-X Executive Director, and Karen Gallant, CARB-X Global R&D Project Director, present details of CARB-X’s four new funding rounds announced April 30, 2019, and answer questions during this webinar. To attend the live webinar, please register by completing the form on the right. Find more information and a registration link here. A recording of the webinar will be available for viewing shortly after the event.

CARB-X 2019 Funding Rounds Webinar2019-05-14T09:19:31+00:00

Enabling academia to fill the discovery gap – Learnings from industry and funders

Speaker: Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Moderator: Laura Piddock, Director Scientific Affairs, GARDP In this webinar, Ursula Theuretzbacher discussed why small companies and academic labs are currently the main drivers of antibiotic R&D and what challenges they face. Topics discussed included: Mainly small companies are active in antibacterial drug R&D and pursue a variety of approaches Main challenges of various antibacterial R&D approaches What to learn from industry and funders How to avoid the most common mistakes

Enabling academia to fill the discovery gap – Learnings from industry and funders2019-08-23T08:03:04+00:00

Infection models for antimicrobial R&D: Intracellular models

Speaker: Françoise van Bambeke, Research Director Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Université catholique de Louvain (Belgium) Moderator: Laura Piddock, Director of Scientific Affairs, GARDP In this webinar, Françoise van Bambeke talked about intracellular activity of antibiotics. Topics discussed included: The role of intracellular survival in chronic infections and its contribution to poor response to antibiotics In vitro models to study intracellular activity of antibiotics Cellular pharmacokinetic (PK) parameters predictive of intracellular potency for antibiotics Cellular pharmacodynamics

Infection models for antimicrobial R&D: Intracellular models2019-08-23T08:01:46+00:00

Find out how GARDP is redoubling its efforts to accelerate the development and delivery of new and improved antibiotics

Speaker: Manica Balasegaram, Executive Director, GARDP Moderator: Jennifer Katz, Director of External Affairs, GARDP In this webinar, Dr Manica Balasegaram, GARDP’s Executive Director highlighted GARDP’s role in accelerating the implementation of WHO’s Global Action Plan, and share GARDP’s updated strategy. This live webinar including interactive Q&A session was broadcast on 26 June 2019. If you have questions or comments, please let us know: revive@gardp.org.

Find out how GARDP is redoubling its efforts to accelerate the development and delivery of new and improved antibiotics2019-07-11T07:46:30+00:00

New initiatives to support AMR innovation (BSAC Spring Conference 2019)

BSAC Spring Conference 2019: Global views, local problems: Innovative solutions to AMR and infection challenges 21 – 22 March 2019, International Convention Centre, Birmingham, UK Parallel session one 'New initiatives to support AMR innovation' co-developed by GARDP and CARB-X Public health driven R&D of antibiotics for priority drug resistant infections Dr Seamus O'Brien, R&D Director, Global Antibiotic R&D Partnership (GARDP) CARB-X: Building A Portfolio of New Antibiotics, Vaccines & Diagnostics with Open Science Dr Richard

New initiatives to support AMR innovation (BSAC Spring Conference 2019)2019-06-07T09:16:01+00:00

Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research

Speaker: William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy Moderator: Peter Warn, Senior Vice President, Anti-infective Discovery, Evotec In this webinar, William J. Weiss introduced experimental design of animal models for antimicrobial research. He discussed questions such as: Where to start and what model to use? Are animal models of bacterial infection reflective of the clinical condition? Are in vivo animal model results predictive of clinical efficacy? This webinar including interactive Q&A session

Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research2020-10-09T08:39:53+00:00

Mining Chemical Libraries for New Antibacterials – Session 2

In this webinar, the recording of Carl Balibar's presentation 'Mining of chemical libraries for new antibacterials' (original webinar on 21 May) was followed by another live Q&A session with Carl. Speaker: Carl Balibar, Principal Scientist, Merck Research Laboratories Moderator: Benjamin Blasco, Discovery Senior Project Manager, GARDP Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening

Mining Chemical Libraries for New Antibacterials – Session 22019-08-23T07:58:38+00:00

Resistance testing – beyond serial passage experiments

Pre-conference workshop: 'Resistance testing – beyond serial passage experiments' 12th Berlin Conference on Life Sciences - Novel Antimicrobials & AMR Diagnostics, 14-15 March 2019, Berlin Emergence of mutational resistance - Threat or myth? Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria Testing of dual/multiple target drugs Michael Mourez, Evotec ID Lyon, France Testing of single target drugs Diarmaid Hughes, Uppsala University & ENABLE, Sweden Jointly organized with:                  

Resistance testing – beyond serial passage experiments2019-04-08T12:19:43+00:00


How to steward new antibiotics into low- and middle-income countries (LMICs)?
– by Marc Mendelson & Adrian Brink

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Despite the many health system challenges faced by resource-poor LMICs, access to new antibiotics used in the treatment of multi-drug resistant (MDR) and extensively-drug resistant (XDR) bacterial infections should be


How to steward new antibiotics into low- and middle-income countries (LMICs)?
– by Marc Mendelson & Adrian Brink
2020-05-07T16:36:40+00:00

Mining Chemical Libraries for New Antibacterials

Speaker: Carl Balibar, Principal Scientist, Merck Research Laboratories Moderator: Benjamin Blasco, Discovery Senior Project Manager, GARDP Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) discussed screen design, target bias, and

Mining Chemical Libraries for New Antibacterials2020-10-09T08:41:15+00:00


The REPAIR Impact Fund: Reflections from the first year
– by Aleks Engel

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Antimicrobial resistance (AMR) is a massive and growing concern worldwide. What can stop it? It is a complex and far-reaching problem with no easy answers, but we are trying to


The REPAIR Impact Fund: Reflections from the first year
– by Aleks Engel
2020-05-07T16:37:09+00:00


Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance
– by Sarah Paulin and Peter Beyer

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” The R&D pipeline for new antibacterials to treat increasingly resistant bacterial infections is virtually dry. Very few classes of new antibiotics in particular to treat Gram-negatives have come to the


Turning the tide on R&D – WHO launches first data call to review pre-clinical pipeline to tackle antibiotic resistance
– by Sarah Paulin and Peter Beyer
2020-05-07T16:37:42+00:00


Time to pull out all the stops in the fight against superbugs
– by Kevin Outterson

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Great progress on push incentives In the Review on Antimicrobial Resistance (AMR), Lord Jim O’Neill called for a Global AMR Fund with $2 billion over five years. In the past


Time to pull out all the stops in the fight against superbugs
– by Kevin Outterson
2020-05-07T16:38:32+00:00


Antibacterial drugs: Clinical development for non-developers
Part 3: Non-traditional approaches

Moderator: David Shlaes, Anti-infectives consulting, retired Speakers: Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA Mair Powell, Senior Clinical Assessor, Health Products Regulatory Authority (Ireland) The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B),


Antibacterial drugs: Clinical development for non-developers
Part 3: Non-traditional approaches
2020-10-09T08:41:56+00:00


NIAID Resources to Facilitate Discovery & Development
of Anti-Infectives

NEW: Download a summary of this webinar here! Speakers: Ann Eakin, Senior Scientific Officer Office of Biodefense, Research Resources & Translational Research, DMID/NIAID/NIH Dan Pevear, Sr. Vice President, Biology and Grants Development, VenatoRx Pharmaceuticals Incorporated Moderator: François Franceschi, Project leader AMREP, GARDP In this webinar, Ann Eakin (US National Institute of Allergy and Infectious Diseases, NIAID) provided an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines and diagnostics


NIAID Resources to Facilitate Discovery & Development
of Anti-Infectives
2020-10-09T08:42:43+00:00


Why we need to prioritize developing antibiotics for children
– by Manica Balasegaram

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” A question I’m frequently asked is “with the rise of drug-resistant infections, how does GARDP decide where to focus its efforts”? It’s a reasonable question. And our approach is simple.


Why we need to prioritize developing antibiotics for children
– by Manica Balasegaram
2020-05-07T16:23:32+00:00

BSAC Antimicrobial Chemotherapy Conference 2019

Antimicrobial Chemotherapy Conference 2019 - An ABC for Everyone Involved in Developing New Antimicrobials 15 January 2019, London Organized by the British Society for Antimicrobial Chemotherapy (BSAC) in collaboration with GARDP Session 1: Antimicrobial drug discovery - an essential overview Opening Remarks Laura Piddock, Head of Scientific Affairs, Global Antibiotic R&D Partnership (GARDP) The risks of clinical development from the perspective of the antibacterial discovery scientist David Shlaes, Former Professor of Medicine, Case Western Reserve University,

BSAC Antimicrobial Chemotherapy Conference 20192019-02-15T09:34:14+00:00

CARB-X: Combating Antibiotic Resistance Globally Webinar

On 15 January 2019, Professor Kevin Outterson, executive director of CARB-X, will be featured in a webinar to introduce and explain the public-private partnership CARB-X, which is dedicated to the early development of innovative antibiotics, vaccines, and other products to fight superbugs. Find more information and a registration link here.

CARB-X: Combating Antibiotic Resistance Globally Webinar2019-01-11T15:19:20+00:00


Recent approvals – do they make a difference?
– by Ursula Theuretzbacher

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” Six new antibiotics have been approved by the U.S. Food and Drug Administration (FDA) over the last four years. So, at a first glance it seems that there is renewed


Recent approvals – do they make a difference?
– by Ursula Theuretzbacher
2020-05-07T16:39:10+00:00

New Strategies in Antibiotic Drug Development

On December 13th, 2018, Collaborative Drug Discovery (CDD) will host a webinar on New Strategies in Antibiotic Drug Development with Dr. Arthur “AJ” Campbell & Dr. Cheryl Quinn. The talk is hosted by CDD, in conjunction with Pew Trusts and moderated by Keystone Symposia CSO Dr. Thale Jarvis with an introduction from Dr. Wes Kim, Senior Officer of Pew Trust's Antibiotic Resistance Project. The discussion will be highly informed with a focus on: How we can move the needle

New Strategies in Antibiotic Drug Development2019-01-11T15:20:58+00:00

Stemming the Superbug Tide: Just a Few Dollars More – Looking at the New OECD Report on AMR

On 11 December, 14:00 GMT, the Leading Health System Network (LHSN), a collaborative network of healthcare leaders and organisations, will host a webinar discussing the OECD report ‘Stemming the Superbug Tide: Just a Few Dollars More’. This report describes the long-term public health and economics consequences of the rise in AMR and identifies effective solutions to tackle this top public health priority. For more information visit the LHSN website.

Stemming the Superbug Tide: Just a Few Dollars More – Looking at the New OECD Report on AMR2019-01-11T15:21:15+00:00


More than one model to stimulate antimicrobial drug development
– by Jim O’Neill

PLEASE NOTE: The Viewpoints on our website are to be read and freely shared by all. If they are republished, the following text should be used: “This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).” When I first started leading the AMR Review in 2014, I soon came to the conclusion that, if the current model wasn’t delivering new antimicrobial drugs, the solution was obvious:


More than one model to stimulate antimicrobial drug development
– by Jim O’Neill
2020-05-07T16:39:46+00:00

The AMR Studio – A podcast by the Uppsala Antibiotic Center

The Uppsala Antibiotic Center launches their newest outreach project, "The AMR Studio", with the occasion of the World Antibiotic Awareness Week 2018. The AMR Studio is a podcast dedicated to highlighting the multidisciplinary research on antimicrobial resistance that is happening around the world. Formatted around interviews with professionals working in all aspects of the topic, they aim to bring the global and trans-sectorial nature of the fight against antimicrobial and antibiotic resistance to anyone with an interest. In

The AMR Studio – A podcast by the Uppsala Antibiotic Center2019-01-11T15:21:59+00:00

External blogs in the field

The views and opinions expressed in this blog are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contributors. GARDP is not responsible for the content of external sites. John H. Rex: Solutions for Antimicrobial Resistance David Shlaes: Antibiotics - The Perfect Storm Longitude Prize - Blog The Center For Disease Dynamics, Economics & Policy (CDDEP)

External blogs in the field2019-03-01T11:51:02+00:00

Making Safety a Part of Drug Design

Speaker: Claire Sadler, Senior Toxicologist, ApconiX, UK Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria * This presentation was also part of the GARDP and CARB-X co-organized session 'Antibiotic Bootcamps for Developers: Preclinical Toxicology' at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance * In this webinar, Claire Sadler discussed the toxicological challenges and pitfalls of antibiotic discovery programs. Potential safety risks are the major reason for terminating a program in early phases of antibiotic

Making Safety a Part of Drug Design2020-10-09T08:43:25+00:00